Effects of dietary L-arginine on structure and function of flow-restricted vein grafts

Journal of Vascular Surgery

Volumn 33, Issue 4, 2001, Pages 829-839

  Landis, Michael E ^a   Ray, Edward C ^b   Gloviczki, Peter ^a   Miller, Virginia M ^a  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; AMINO ACID; ARGININE; BRIMONIDINE; CALCIMYCIN; NITRIC OXIDE; QUINOXALINE DERIVATIVE;

ANIMAL; ARTICLE; BLOOD; BLOOD FLOW VELOCITY; DIET SUPPLEMENTATION; DOG; DOSE RESPONSE; DRUG EFFECT; FEMORAL ARTERY; IN VITRO STUDY; MALE; MUSCLE CONTRACTION; MUSCLE RELAXATION; PATHOLOGY; PHYSIOLOGY; SAPHENOUS VEIN; STENOSIS, OCCLUSION AND OBSTRUCTION; TRANSPLANTATION; VASCULAR ENDOTHELIUM; VASCULAR PATENCY; VASCULAR SMOOTH MUSCLE;

ADRENERGIC ALPHA-AGONISTS; AMINO ACIDS; ANIMALS; ARGININE; BLOOD FLOW VELOCITY; CALCIMYCIN; CONSTRICTION, PATHOLOGIC; DIETARY SUPPLEMENTS; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; FEMORAL ARTERY; MALE; MUSCLE CONTRACTION; MUSCLE RELAXATION; MUSCLE, SMOOTH, VASCULAR; NITRIC OXIDE; QUINOXALINES; SAPHENOUS VEIN; VASCULAR PATENCY;

EID: 0035316199     PISSN: 07415214     EISSN: None     Source Type: Journal    
DOI: 10.1067/mva.2001.111987     Document Type: Article

References (47)

1. Clowes AW. Intimal hyperplasia and graft failure. Cardiovasc Pathol 1993;2:179S.
2. Davies MG, Hagen P-O. Pathobiology of intimai hyperplasia. Br J Surg 1994;81:1254-69.
3. Cooke JP, Singer AH, Tsao P, Zera P, Rowan KA, Billingham ME. Antiatherogenic effects of L-arginine in the hypercholesterolemic rabbit. J Clin Invest 1992;90:1168-72.
4. Davies MG, Hagen P-O. Suppression of intimal hyperplasia in experimental vein grafts by oral L-arginine supplementation and single ex-vivo immersion in deferoxamine manganese. J Vasc Surg 1996;23; 410-20.
5. Davies MG, Dalen H, Kim JH, Barber L, Svendsen E, Hagen P-O. Control of accelerated vein graft atheroma with the nitric oxide precursor: L-arginine. J Surg Res 1995;59:35-42.
6. Davies MG, Kim JH, Dalen H, Makhoul RG, Svendsen E, Hagen P-O. Reduction of experimental vein graft intimai hyperplasia and preservation of nitric oxide-mediated relaxation by the nitric oxide precursor L-arginine. Surgery 1994;116:557-68.
7. Cayatte AJ, Palacino JJ, Horten K, Cohen RA. Chronic inhibition of nitric oxide production accelerates neointima formation and impairs endothelial function in hypercholesterolemic rabbits, Arterioscler Thromb 1994;14:753-9.
8. Theilmeier G, Chan JR, Zalpour C, Anderson B, Wang BY, Wolf A, et al. Adhesiveness of mononuclear cells in hypercholesterolemic humans is normalized by dietary L-arginine. Arterioscler Thromb Vasc Biol 1997;17:3557-64.
9. Boger RH, Bode-Boger SM, Kienke S, Stan AC, Nafe R, Frolich JC. Dietary L-arginine decreases myointimal cell proliferation and vascular monocyte accumulation in cholesterol-fed rabbits. Atherosclerosis 1998;136:67-77.
10. Boger RH, Bode-Boger SM, Szuba A, Tsao PS, Chan JR, Tangphao O, et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction - its role in hypercholesterolemia, Circulation 1998;99:1842-7.
11. Chin-Dusting JP, Alexander CT, Arnold PJ, Hodgson WC, Lux AS, Jennings GL. Effects of in vivo and in vitro L-arginine e supplementation on healthy human vessels. J Cardiovasc Pharmacol 1996;28: 158-66.
12. Bode-Boger SM, Boger RH, Galland A, Tsikas D, Frolich JC. L-arginine -induced vasodilation in healthy humans: pharmacokinetic-pharmacodynamic relationship. Br J Clin Pharmacol 1998;46:489-97.
13. Cooke JP, Dzau VJ. Derangements of the nitric oxide synthase pathway, L-arginine, and cardiovascular diseases. Circulation 1997;96:379-82.
14. Lou H, Kodama T, Wang YN, Katz N, Ramwell P, Foegh ML. L-arginine prevents heart transplant arteriosclerosis by modulating the vascular cell proliferative response to insulin-like growth factor-I and interleukin-6, J Heart Lung Transplant 1996;15:1248-57.
15. Mugge A, Harrison DG. L-arginine does not restore endothelial dysfunction in atherosclerotic rabbit aorta in vivo. Blood Vessels 1991;28:354-7.
16. Gregory CR, Cooke JP, Patz JD, Berryman ER, Shorthouse R, Morris RE. Enhanced nitric oxide production induced by the administration of L-arginine does not inhibit arterial neointimal formation after overwhelming alloimmune injury, J Heart Lung Transplant 1996;15:58-66.
17. Gonzalez C, Regunathan S, Reis DJ, Estrada C. Agmatine, an endogenous modulator of noradrenergic neurotransmission in the rat tail artery. Br J Pharrnacol 1996;119:677-84.
18. Galea E, Regunathan S, Eliopoulos V, Feinstein DL, Reis DJ. Inhibition of mammalian nitric oxide synthases by agmatine, an endogenous polyamine formed by decarboxylation of arginine. Biochern J 1996;316:247-9.
19. Grant SK, Green BG, Stiffey-Wilusz J, Durette PL, Shah SK, Kozarich JW. Structural requirements for human inducible nitric oxide synthase substrates and substrate analogue inhibitors. Biochemistry 1998;37; 4174-80.
20. Nakaki T, Kato R. Beneficial circulatory effect of L-arginine. Jpn J Pharmacol 1994;66:167-71.
21. G-hydroxy-L-arginine during high-output NO production. Am J Physiol 1996;271:H1988-98.
22. Wang WW, Jenkinson CP, Griscavage JM, Kern RM, Arabolos NS, Byrns RE, et al. Co-induction of arginase and nitric oxide synthase in murine macrophages activated by lipopolysaccharide. Biochem Biophys Res Commun 1995;210:1009-16.
23. Kontos HA, Wei EP. Arginine analogues inhibit responses mediated by ATP-sensitive K+ channels. Am J Physiol 1996;271:H1498-506.
24. Cambria RA, Lowell RC, Gloviczki P, Miller VM. Chronic changes in blood flow alter endothelium-dependent responses in autogenous vein grafts in dogs. J Vasc Surg 1994;20:765-73.
25. Braman RS, Hendrix SA. Nanogram nitrite and nitrate determination in environmental and biological materials by vanadium (III) reduction with chemiluminescence detection. Anal Chem 1989;61:2715-8.
26. Panza JA, Casino PR, Badar DM, Quyyumi AA. Effect of increased availability of endothelium-derived nitric oxide precursor on endothelium-dependent vascular relaxation in normal subjects and patients with essential hypertension. Circulation 1993;87:1475-81.
27. Rhee RY, Gloviczki P, Miller VM. An arginine analog inhibits responses of both the endotheliurn and smooth muscle of canine in situ vein grafts. Cardiovasc Surg 1997;5:169-75.
28. Miller VM, Barber DA. Modulation of endothelim-derived nitric oxide in canine femoral veins. Am J Physiol 1996;271:H668-73.
29. Flavahan NA, Miller VM, Aarhus LL, Vanhoutte PM. Denervation augments alpha-2 but not alpha-1 adrenergic responses in canine saphenous veins. J Pharmacol Exp Ther 1987;240:589-93.
30. Miller VM, Reigel MM, Hollier LH, Vanhoutte PM. Endothelium-dependent responses in autogenous femoral veins grafted into the arterial circulation of the dog. J Clin Invest 1987;80:1350-7.
31. Luscher TF, Diederich D, Siebenmann R, Lehmann K, Stulz P, von Segesser L, et al. Difference between endothelium-dependent relaxation in arterial and in venous coronary bypass grafts. N Engl J Med 1988;319:462-7.
32. Ku DD, Caulfield JB, Kirklin JK. Endothelium-dependent responses in long-term human coronary artery bypass grafts. Circulation 1991;83:402-11.
33. Clouse WD, Rud KS, Hurt RD, Miller VM. Short-term treatment with transdermal nicotine affects function of canine saphenous veins. Vasc Med 2000;5:75-82.
34. Palmer RM, Ferrige AG, Moncada S, Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987;327:524-6.
35. Drexler H, Zeiher AM, Just H. Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolemic patients by L-arginine, Lancet 1991;338:1546-50.
36. Creager MA, Gallagher SJ, Girerd XJ, Coleman SM, Dzau VJ, Cooke JP. L-arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. J Clin Invest 1992;90:1248-53.
37. Houston DS, Shepherd JT, Vanhoutte PM, Adenine nucleotides, serotonin, and endothelium-dependent relaxations to platelets. Am J Physiol 1985;248:H389-95.
38. Kontos HA, Wei EP. Cerebral arteriolar dilations by KATP channel activators need L-lysine or L-arginine. Am J Physiol 1998;274:H974-81.
39. Yang J, Yu M, Jan YN, Jan LY. Stabilization of ion selectivity filter by pore loop ion pairs in an inwardly rectifying potassium channel. Proc Natl Acad Sci U S A 1997;94:1568-72.
40. Miller VM, Flavahan NA, Vanhoutte PM. Pertussis toxin reduces endothelium-dependent and independent responses to alpha2-adrenergic stimulation in systemic canine arteries and veins. J Pharmacol Exp Ther 1991;257:290-3.
41. Niu XW, Meech RW, The effect of polyamines on KATP channels in guinea-pig ventricular myocytes. J Physiol 1998;508:401-11.
42. Szabo C, Southan GJ, Thiemermann C, Vane JR. The mechanism of the inhibitory effect of polyamines on the induction of nitric oxide syn-thase: role of aldehyde metabolites. Br J Pharmacol 1994;113:757-66.
43. Regunathan S, Youngson C, Wang H, Reis DJ. Imidazoline receptors in vascular smooth muscle and endothelial cells. Ann N Y Acad Sci 1995;763:580-90.
44. Morrissey JJ, Klahr S. Agmatine activation of nitric oxide synthase in endothelial cells. Proc Assoc Am Physicians 1997;109:51-7.
45. Ray EC, Landis ME, Miller VM. Effects of dietary L-arginine on reactivity of canine coronary arteries. Vasc Med 1999;4:211-7.
46. Bode-Boger SM, Boger RH, Kienke S, Junker W, Frolich JC. Elevated L-arginine /dimethylarginine ratio contributes to enhanced systemic NO production in dietary L-arginine in hypercholesterolemic rabbits. Biochem Biophys Res Commun 1996;219:598-603.
47. Azuma H, Sato J, Hamasaki H, Sugimoto A, Isotani E, Obayashi S. Accumulation of endogenous inhibitors for nitric oxide synthesis and decreased content of L-arginine in regenerated endothelial cells. Br J Pharmacol 1995;115:1001-4.